ArticleScience advances2026
A folate receptor-targeted NIR-II probe improves intraoperative imaging and surgery of metastatic ovarian cancer.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intraoperative fluorescence imaging holds great promise for achieving complete cytoreduction in ovarian cancer, but its clinical utility is currently constrained by the limitations of existing imaging agents. In particular, the leading clinical probe, OTL38, operates in the near-infrared I (NIR-I; 700 to 1000 nanometers) window, which suffers from limited tissue penetration and suboptimal resolution. Here, a folate receptor α (FRα)-targeted NIR-II (1000 to 3000 nanometers) imaging probe was developed by incorporating a 4-(4-iodophenyl)butanoic acid moiety. This structural modification enables albumin binding, thereby prolonging systemic circulation and enhancing accumulation in FRα-positive tumors. In murine models of peritoneal metastasis, our probe enabled precise visualization of occult lesions undetectable by the naked eye. Compared to OTL38, this probe demonstrated superior tumor detection sensitivity (90.20% versus 78.75%) and allowed for the reliable identification of elusive lesions less than or equal to 3 millimeters in diameter. These findings highlight the potential of albumin-binding NIR-II imaging strategies to overcome the limitations of current clinical probes and enhance precision fluorescence-guided surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.